Mechanism of VB-111 in Treating Ovarian Cancer: Bradley Monk, MD, FACOG, FACS
Bradley Monk, MD, FACOG, FACS, discusses the mechanism of VB-111 in patients with ovarian cancer.
This content originally appeared on our sister site, OncLive.
VB-111 is a targeted anticancer viral gene therapy that is based on a non-replicating, non-integrating adenovirus 5 vector that contains a transgene expressed solely in angiogenic blood vessels.
OncLive spoke with Bradley Monk, MD, FACOG, FACS, a gynecologic oncologist at Arizona Oncology, about the mechanism of action of VB-111 in patients with ovarian cancer.
The agent has a dual mechanism of action, Monk says. The agent targets endothelial cells, which causes vascular disruption and results in tumor starvation, and induces immune response through local inflammation, Monk concludes.
Bendamustine Is an Effective Alternative to Fludarabine-Based Lymphodepletion in LBCL
December 7th 2024In the wake of fludarabine shortages, lemphodepletion with bendamustine was found to be an effective alternative compared for patients with large B-cell lymphoma being treated with a CD19-directed CAR T-cell therapy.
